EP2992094A4 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES - Google Patents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES

Info

Publication number: EP2992094A4
Authority: EP; European Patent Office
Prior art keywords: diabetes; compositions; treatment; methods; type
Prior art date: 2013-05-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP14791797.5A

Other languages

German (de)

French (fr)

Other versions

EP2992094B1 (en

EP2992094A1 (en

Inventor

Bart O Roep

William H Robinson

Paul Utz

Hideki Garren

Lawrence Steinman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

TOLERION

Original Assignee

TOLERION

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-02

Filing date

2014-05-01

Publication date

2016-12-28

2014-05-01 Application filed by TOLERION filed Critical TOLERION

2014-05-01 Priority to HRP20181445TT priority Critical patent/HRP20181445T1/en

2014-05-01 Priority to PL14791797T priority patent/PL2992094T3/en

2014-05-01 Priority to SI201430885T priority patent/SI2992094T1/en

2016-03-09 Publication of EP2992094A1 publication Critical patent/EP2992094A1/en

2016-12-28 Publication of EP2992094A4 publication Critical patent/EP2992094A4/en

2018-06-20 Application granted granted Critical

2018-06-20 Publication of EP2992094B1 publication Critical patent/EP2992094B1/en

Status Not-in-force legal-status Critical Current

2034-05-01 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP14791797.5A 2013-05-02 2014-05-01 Compositions and methods for treatment of type 1 diabetes Not-in-force EP2992094B1 (en)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
HRP20181445TT HRP20181445T1 (en)	2013-05-02	2014-05-01	COMPOSITIONS AND PROCEDURES FOR TYPE 1 DIABETES TREATMENT
PL14791797T PL2992094T3 (en)	2013-05-02	2014-05-01	Compositions and methods for treatment of type 1 diabetes
SI201430885T SI2992094T1 (en)	2013-05-02	2014-05-01	Compositions and methods for treatment of type 1 diabetes

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361818671P	2013-05-02	2013-05-02
PCT/US2014/036394 WO2014179586A1 (en)	2013-05-02	2014-05-01	Compositions and methods for treatment of type 1 diabetes

Publications (3)

Publication Number	Publication Date
EP2992094A1 EP2992094A1 (en)	2016-03-09
EP2992094A4 true EP2992094A4 (en)	2016-12-28
EP2992094B1 EP2992094B1 (en)	2018-06-20

Family

ID=51843952

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14791797.5A Not-in-force EP2992094B1 (en)	2013-05-02	2014-05-01	Compositions and methods for treatment of type 1 diabetes

Country Status (14)

Country	Link
US (2)	US20160068585A1 (en)
EP (1)	EP2992094B1 (en)
JP (2)	JP2016518844A (en)
CN (1)	CN105408478A (en)
CY (1)	CY1120861T1 (en)
DK (1)	DK2992094T3 (en)
ES (1)	ES2687189T3 (en)
HR (1)	HRP20181445T1 (en)
HU (1)	HUE040421T2 (en)
LT (1)	LT2992094T (en)
PL (1)	PL2992094T3 (en)
PT (1)	PT2992094T (en)
SI (1)	SI2992094T1 (en)
WO (1)	WO2014179586A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6895148B1 (en) *	2020-03-31	2021-06-30	クラシエホールディングス株式会社	A marker for determining that the cause of coldness in cold holders is decreased renal function, abnormal water metabolism or adrenal fatigue, and the cause of coldness in cold holders is decreased renal function, abnormal water metabolism or adrenal fatigue. Judgment method for determining that, and a determination kit for determining that the cause of coldness in a cold person is decreased renal function, abnormal water metabolism, or adrenal fatigue.
JP2023542341A (en) *	2020-09-21	2023-10-06	エスアールアイインターナショナル	Targeted antigen delivery system and its use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002045735A2 (en) *	2000-12-08	2002-06-13	University Technologies International, Inc.	Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus
WO2012015903A1 (en) *	2010-07-27	2012-02-02	Bayhill Therapeutics, Inc.	Treatment of type i diabetes mellitus (t1dm) in young newly diagnosed patients

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120035105A1 (en) *	2009-01-09	2012-02-09	Sdg, Inc.	Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
WO2010151420A1 (en) *	2009-06-05	2010-12-29	Bayhill Therapeutics, Inc.	Compositions and methods for treatment of insulin-dependent diabetes mellitus

2014
- 2014-05-01 CN CN201480038111.XA patent/CN105408478A/en active Pending
- 2014-05-01 ES ES14791797.5T patent/ES2687189T3/en active Active
- 2014-05-01 JP JP2016512043A patent/JP2016518844A/en not_active Withdrawn
- 2014-05-01 HU HUE14791797A patent/HUE040421T2/en unknown
- 2014-05-01 US US14/888,639 patent/US20160068585A1/en not_active Abandoned
- 2014-05-01 HR HRP20181445TT patent/HRP20181445T1/en unknown
- 2014-05-01 PL PL14791797T patent/PL2992094T3/en unknown
- 2014-05-01 WO PCT/US2014/036394 patent/WO2014179586A1/en not_active Ceased
- 2014-05-01 PT PT14791797T patent/PT2992094T/en unknown
- 2014-05-01 DK DK14791797.5T patent/DK2992094T3/en active
- 2014-05-01 SI SI201430885T patent/SI2992094T1/en unknown
- 2014-05-01 LT LTEP14791797.5T patent/LT2992094T/en unknown
- 2014-05-01 EP EP14791797.5A patent/EP2992094B1/en not_active Not-in-force
2018
- 2018-09-06 CY CY181100931T patent/CY1120861T1/en unknown
- 2018-11-21 US US16/197,578 patent/US20190315827A1/en not_active Abandoned
2019
- 2019-02-04 JP JP2019017697A patent/JP2019080574A/en active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002045735A2 (en) *	2000-12-08	2002-06-13	University Technologies International, Inc.	Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus
WO2012015903A1 (en) *	2010-07-27	2012-02-02	Bayhill Therapeutics, Inc.	Treatment of type i diabetes mellitus (t1dm) in young newly diagnosed patients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BART O ROEP ET AL: "Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC, vol. 5, no. 191, 26 June 2013 (2013-06-26), pages - 9, XP009170924, ISSN: 1946-6234, DOI: 10.1126/SCITRANSLMED.3006103 *
See also references of WO2014179586A1 *

Also Published As

Publication number	Publication date
EP2992094B1 (en)	2018-06-20
US20160068585A1 (en)	2016-03-10
JP2019080574A (en)	2019-05-30
HRP20181445T1 (en)	2018-11-16
JP2016518844A (en)	2016-06-30
US20190315827A1 (en)	2019-10-17
WO2014179586A1 (en)	2014-11-06
ES2687189T3 (en)	2018-10-24
EP2992094A1 (en)	2016-03-09
HUE040421T2 (en)	2019-03-28
PT2992094T (en)	2018-10-18
SI2992094T1 (en)	2018-12-31
CN105408478A (en)	2016-03-16
DK2992094T3 (en)	2018-09-03
CY1120861T1 (en)	2019-12-11
LT2992094T (en)	2018-11-12
PL2992094T3 (en)	2019-03-29

Publication	Publication Date	Title
FR24C1025I2 (en)	2025-06-20	COMPOSITIONS AND METHODS FOR TREATING ANEMIA
EP3555077A4 (en)	2021-01-06	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP3377516A4 (en)	2019-06-26	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2983791A4 (en)	2016-11-09	METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3013957A4 (en)	2016-08-24	COMPOSITIONS AND METHODS FOR SAMPLE PROCESSING
EP3302379A4 (en)	2019-01-23	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PTÉRYGION
EP2800579A4 (en)	2015-08-19	METHODS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES
EP3374502A4 (en)	2019-07-10	METHODS FOR THE TREATMENT OF CORNEAL DYSTROPHIES
EP3003049A4 (en)	2016-12-07	COMPOSITIONS AND METHODS FOR ACTIVATION OF GERMINATION
EP2836482A4 (en)	2015-12-09	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP2851429A4 (en)	2015-10-14	PROTEIN AND PROTEIN CONJUGATE FOR THE TREATMENT OF DIABETES AND RELATED APPLICATIONS
EP3341391A4 (en)	2019-03-06	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
EP2947990A4 (en)	2016-07-06	COMPOSITIONS AND METHODS FOR TREATING HARMFUL ORGANISMS
EP2688594A4 (en)	2014-07-30	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2830661A4 (en)	2016-05-18	DIAGNOSTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3390642A4 (en)	2019-06-26	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PIGMENT RETINITY 18 AND PIGMENT RETINITY 13
EP2945639A4 (en)	2016-09-28	METHODS OF TREATING HEART CONDITIONS
EP2931279A4 (en)	2016-05-11	METHODS FOR THE TREATMENT OF PRURIT
EP2919759A4 (en)	2016-07-20	MATERIALS AND METHODS USEFUL FOR THE TREATMENT OF GLIOBLASTOMA
EP3405172A4 (en)	2019-09-18	METHODS AND COMPOSITIONS FOR THE TREATMENT OF SKIN AGING
EP3015107A4 (en)	2016-07-06	TREATMENT AGENT FOR THE DYSFUNCTION OF MEIBOMIUS GLANDS
EP2968478A4 (en)	2016-09-07	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA
EP2830644A4 (en)	2015-10-21	METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF NEUROPATHY
EP3403099A4 (en)	2019-09-04	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2863939A4 (en)	2015-12-30	COMPOSITIONS AND METHODS FOR THE TREATMENT OF VITILIGO

Legal Events

Date	Code	Title	Description
2016-02-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-03-09	17P	Request for examination filed	Effective date: 20151130
2016-03-09	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-03-09	AX	Request for extension of the european patent	Extension state: BA ME
2016-04-13	RIN1	Information on inventor provided before grant (corrected)	Inventor name: GARREN, HIDEKI Inventor name: ROEP, BART, O. Inventor name: STEINMAN, LAWRENCE Inventor name: ROBINSON, WILLIAM, H. Inventor name: UTZ, PAUL
2016-08-10	DAX	Request for extension of the european patent (deleted)
2016-11-22	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602014027341 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12N0015000000 Ipc: A61K0048000000
2016-12-28	A4	Supplementary search report drawn up and despatched	Effective date: 20161128
2016-12-28	RIC1	Information provided on ipc code assigned before grant	Ipc: C12N 15/85 20060101ALI20161122BHEP Ipc: C07K 14/62 20060101ALI20161122BHEP Ipc: A61K 48/00 20060101AFI20161122BHEP
2017-12-20	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2017-12-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-01-17	INTG	Intention to grant announced	Effective date: 20171221
2018-04-23	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2018-05-18	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2018-05-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2018-06-20	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-06-20	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2018-07-11	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2018-07-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1010092 Country of ref document: AT Kind code of ref document: T Effective date: 20180715
2018-07-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602014027341 Country of ref document: DE
2018-08-28	REG	Reference to a national code	Ref country code: RO Ref legal event code: EPE
2018-09-03	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20180827
2018-09-05	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2018-09-10	REG	Reference to a national code	Ref country code: HR Ref legal event code: TUEP Ref document number: P20181445 Country of ref document: HR
2018-09-18	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2018-10-18	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Ref document number: 2992094 Country of ref document: PT Date of ref document: 20181018 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20180911
2018-10-24	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2687189 Country of ref document: ES Kind code of ref document: T3 Effective date: 20181024
2018-11-05	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20180620
2018-11-16	REG	Reference to a national code	Ref country code: HR Ref legal event code: T1PR Ref document number: P20181445 Country of ref document: HR
2018-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180620
2019-02-04	REG	Reference to a national code	Ref country code: SK Ref legal event code: T3 Ref document number: E 28747 Country of ref document: SK
2019-02-08	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20180402671 Country of ref document: GR Effective date: 20190125
2019-02-15	REG	Reference to a national code	Ref country code: EE Ref legal event code: FG4A Ref document number: E016572 Country of ref document: EE Effective date: 20180913
2019-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180620
2019-03-21	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602014027341 Country of ref document: DE
2019-03-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E040421 Country of ref document: HU
2019-04-26	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2019-04-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2019-05-29	26N	No opposition filed	Effective date: 20190321
2019-05-31	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20181445 Country of ref document: HR Payment date: 20190419 Year of fee payment: 6
2019-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180620
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180620
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180620
2020-05-15	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20181445 Country of ref document: HR Payment date: 20200423 Year of fee payment: 7
2020-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FI Payment date: 20200528 Year of fee payment: 7 Ref country code: ES Payment date: 20200601 Year of fee payment: 7 Ref country code: EE Payment date: 20200421 Year of fee payment: 7 Ref country code: CY Payment date: 20200430 Year of fee payment: 7 Ref country code: DE Payment date: 20200528 Year of fee payment: 7 Ref country code: LU Payment date: 20200527 Year of fee payment: 7 Ref country code: NO Payment date: 20200528 Year of fee payment: 7 Ref country code: CZ Payment date: 20200428 Year of fee payment: 7 Ref country code: IE Payment date: 20200527 Year of fee payment: 7 Ref country code: DK Payment date: 20200528 Year of fee payment: 7 Ref country code: RO Payment date: 20200423 Year of fee payment: 7 Ref country code: GR Payment date: 20200528 Year of fee payment: 7 Ref country code: FR Payment date: 20200525 Year of fee payment: 7 Ref country code: NL Payment date: 20200526 Year of fee payment: 7 Ref country code: LT Payment date: 20200421 Year of fee payment: 7 Ref country code: PT Payment date: 20200424 Year of fee payment: 7 Ref country code: CH Payment date: 20200603 Year of fee payment: 7
2020-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LV Payment date: 20200423 Year of fee payment: 7 Ref country code: IS Payment date: 20200420 Year of fee payment: 7 Ref country code: SK Payment date: 20200420 Year of fee payment: 7 Ref country code: BE Payment date: 20200527 Year of fee payment: 7 Ref country code: BG Payment date: 20200521 Year of fee payment: 7 Ref country code: PL Payment date: 20200423 Year of fee payment: 7 Ref country code: GB Payment date: 20200527 Year of fee payment: 7 Ref country code: HR Payment date: 20200423 Year of fee payment: 7 Ref country code: SE Payment date: 20200601 Year of fee payment: 7 Ref country code: IT Payment date: 20200522 Year of fee payment: 7 Ref country code: SI Payment date: 20200421 Year of fee payment: 7 Ref country code: HU Payment date: 20200503 Year of fee payment: 7
2020-09-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MT Payment date: 20200420 Year of fee payment: 7 Ref country code: AT Payment date: 20200421 Year of fee payment: 7
2021-11-17	REG	Reference to a national code	Ref country code: HR Ref legal event code: PBON Ref document number: P20181445 Country of ref document: HR Effective date: 20210501
2021-11-25	REG	Reference to a national code	Ref country code: LT Ref legal event code: MM4D Effective date: 20210501
2021-12-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602014027341 Country of ref document: DE
2021-12-14	REG	Reference to a national code	Ref country code: FI Ref legal event code: MAE
2021-12-15	REG	Reference to a national code	Ref country code: EE Ref legal event code: MM4A Ref document number: E016572 Country of ref document: EE Effective date: 20210531
2021-12-20	REG	Reference to a national code	Ref country code: DK Ref legal event code: EBP Effective date: 20210531
2021-12-27	REG	Reference to a national code	Ref country code: NO Ref legal event code: MMEP
2021-12-28	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2021-12-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2022-01-05	REG	Reference to a national code	Ref country code: NL Ref legal event code: MM Effective date: 20210601
2022-01-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MM01 Ref document number: 1010092 Country of ref document: AT Kind code of ref document: T Effective date: 20210501
2022-01-26	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20210501
2022-01-26	REG	Reference to a national code	Ref country code: SK Ref legal event code: MM4A Ref document number: E 28747 Country of ref document: SK Effective date: 20210501
2022-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210502 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210502 Ref country code: HR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: NO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211102 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: LT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531
2022-02-09	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20210531
2022-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210502 Ref country code: LV Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211207
2022-02-28	REG	Reference to a national code	Ref country code: SI Ref legal event code: KO00 Effective date: 20220127
2022-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211201
2022-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1010092 Country of ref document: AT Kind code of ref document: T Effective date: 20180620
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210601 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180620
2022-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531
2022-08-01	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20220801
2022-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210502
2023-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501
2023-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200501
2025-09-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210501
2025-10-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211103